Los Angeles Capital Management & Equity Research Inc. acquired a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,458 shares of the specialty pharmaceutical company’s stock, valued at approximately $542,000. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.08% of AMAG Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue boosted its stake in AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 3,081 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after acquiring an additional 510 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after acquiring an additional 5,005 shares in the last quarter. Mason Street Advisors LLC boosted its stake in AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after acquiring an additional 554 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after acquiring an additional 54 shares in the last quarter.

Several equities analysts have issued reports on the stock. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Cantor Fitzgerald restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Deutsche Bank AG set a $24.00 price objective on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, July 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.92.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 18.20 on Friday. AMAG Pharmaceuticals, Inc. has a one year low of $16.00 and a one year high of $36.83. The stock has a 50 day moving average of $18.17 and a 200-day moving average of $19.80. The stock’s market capitalization is $642.24 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. During the same period in the previous year, the business posted $1.45 EPS. The company’s quarterly revenue was up 24.3% on a year-over-year basis. Equities analysts predict that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

In other news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/los-angeles-capital-management-equity-research-inc-takes-position-in-amag-pharmaceuticals-inc-amag/1584297.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.